Aytu Historical Income Statement

AYTU Stock

USD 2.37 0.01 0.42%

Historical analysis of Aytu BioScience income statement accounts such as Interest Expense of 5.2 M, Selling General Administrative of 27.2 M or Other Operating Expenses of 104.2 M can show how well Aytu BioScience performed in making a profits. Evaluating Aytu BioScience income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Aytu BioScience's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Aytu BioScience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aytu BioScience is a good buy for the upcoming year.

Net Income Gross Profit

Build AI portfolio with Aytu Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.

About Aytu Income Statement Analysis

Aytu BioScience Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Aytu BioScience shareholders. The income statement also shows Aytu investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Aytu BioScience Income Statement Chart

At this time, Aytu BioScience's Non Operating Income Net Other is comparatively stable compared to the past year.

Selling General Administrative Other Operating Expenses Total Operating Expenses Total Revenue

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Aytu BioScience. It is also known as Aytu BioScience overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Total Revenue

Total revenue comprises all receipts Aytu BioScience generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from Aytu BioScience's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Aytu BioScience current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aytu BioScience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Aytu Stock please use our How to Invest in Aytu BioScience guide.At this time, Aytu BioScience's Non Operating Income Net Other is comparatively stable compared to the past year.

	2022	2023	2024	2025 (projected)
Gross Profit	66.6M	54.6M	62.8M	65.9M
Total Revenue	107.4M	81.0M	93.2M	97.8M

Gross Profit Total Revenue

Aytu BioScience income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Net Income From Continuing Ops	Research Development	Cost Of Revenue	Tax Provision	Interest Income	Non Recurring	Net Interest Income	Non Operating Income Net Other	Selling And Marketing Expenses	Reconciled Depreciation
Depreciation And Amortization		0.4	0.81	0.85	0.38	-0.38	-0.01	0.87	-0.36	-0.07	-0.35	-0.09	0.9	0.94	-0.37	0.38	0.73	0.65	-0.19	-0.71	0.08	0.7	0.84	0.62
Interest Expense	0.4		0.45	0.55	0.63	-0.71	-0.6	0.53	-0.94	-0.04	-0.89	-0.07	0.44	0.34	-0.94	0.9	0.62	-0.13	-0.09	-0.29	-0.07	0.31	0.51	0.62
Selling General Administrative	0.81	0.45		0.91	-0.02	-0.64	-0.37	0.93	-0.58	-0.29	-0.6	0.01	0.84	0.81	-0.59	0.32	0.79	0.44	-0.03	-0.95	0.31	0.71	0.89	0.61
Other Operating Expenses	0.85	0.55	0.91		0.16	-0.47	-0.16	1.0	-0.6	-0.35	-0.57	-0.12	0.97	0.94	-0.61	0.53	0.95	0.49	-0.21	-0.78	0.02	0.78	0.98	0.78
Operating Income	0.38	0.63	-0.02	0.16		-0.14	0.01	0.14	-0.36	0.3	-0.32	-0.08	0.22	0.22	-0.36	0.61	0.21	0.06	-0.33	0.13	-0.24	0.04	0.16	0.32
Ebit	-0.38	-0.71	-0.64	-0.47	-0.14		0.93	-0.49	0.83	0.0	0.83	-0.12	-0.31	-0.24	0.83	-0.57	-0.41	0.16	-0.43	0.53	-0.3	-0.27	-0.41	-0.33
Ebitda	-0.01	-0.6	-0.37	-0.16	0.01	0.93		-0.19	0.75	-0.02	0.76	-0.17	0.03	0.11	0.74	-0.46	-0.15	0.41	-0.55	0.29	-0.3	-0.02	-0.11	-0.12
Total Operating Expenses	0.87	0.53	0.93	1.0	0.14	-0.49	-0.19		-0.58	-0.33	-0.56	-0.11	0.97	0.94	-0.6	0.5	0.92	0.5	-0.18	-0.81	0.05	0.79	0.97	0.76
Income Before Tax	-0.36	-0.94	-0.58	-0.6	-0.36	0.83	0.75	-0.58		0.24	0.98	-0.09	-0.44	-0.33	1.0	-0.84	-0.64	0.14	-0.06	0.44	0.02	-0.28	-0.55	-0.6
Total Other Income Expense Net	-0.07	-0.04	-0.29	-0.35	0.3	0.0	-0.02	-0.33	0.24		0.3	-0.52	-0.34	-0.3	0.25	-0.13	-0.35	-0.42	0.05	0.26	0.3	0.02	-0.31	-0.42
Net Income	-0.35	-0.89	-0.6	-0.57	-0.32	0.83	0.76	-0.56	0.98	0.3		-0.24	-0.42	-0.31	0.98	-0.77	-0.6	0.13	-0.04	0.48	0.03	-0.19	-0.54	-0.54
Income Tax Expense	-0.09	-0.07	0.01	-0.12	-0.08	-0.12	-0.17	-0.11	-0.09	-0.52	-0.24		-0.12	-0.12	-0.09	-0.07	-0.14	0.02	0.22	-0.02	-0.13	-0.59	-0.06	-0.26
Total Revenue	0.9	0.44	0.84	0.97	0.22	-0.31	0.03	0.97	-0.44	-0.34	-0.42	-0.12		0.99	-0.46	0.47	0.91	0.62	-0.27	-0.71	-0.04	0.78	0.96	0.76
Gross Profit	0.94	0.34	0.81	0.94	0.22	-0.24	0.11	0.94	-0.33	-0.3	-0.31	-0.12	0.99		-0.35	0.38	0.85	0.69	-0.27	-0.7	-0.03	0.77	0.92	0.72
Net Income From Continuing Ops	-0.37	-0.94	-0.59	-0.61	-0.36	0.83	0.74	-0.6	1.0	0.25	0.98	-0.09	-0.46	-0.35		-0.84	-0.65	0.11	-0.06	0.44	0.02	-0.29	-0.56	-0.62
Research Development	0.38	0.9	0.32	0.53	0.61	-0.57	-0.46	0.5	-0.84	-0.13	-0.77	-0.07	0.47	0.38	-0.84		0.6	-0.06	0.02	-0.07	-0.33	0.28	0.46	0.62
Cost Of Revenue	0.73	0.62	0.79	0.95	0.21	-0.41	-0.15	0.92	-0.64	-0.35	-0.6	-0.14	0.91	0.85	-0.65	0.6		0.33	-0.26	-0.65	-0.08	0.7	0.95	0.8
Tax Provision	0.65	-0.13	0.44	0.49	0.06	0.16	0.41	0.5	0.14	-0.42	0.13	0.02	0.62	0.69	0.11	-0.06	0.33		-0.17	-0.43	0.06	0.53	0.46	0.52
Interest Income	-0.19	-0.09	-0.03	-0.21	-0.33	-0.43	-0.55	-0.18	-0.06	0.05	-0.04	0.22	-0.27	-0.27	-0.06	0.02	-0.26	-0.17		0.14	0.35	-0.09	-0.25	-0.28
Non Recurring	-0.71	-0.29	-0.95	-0.78	0.13	0.53	0.29	-0.81	0.44	0.26	0.48	-0.02	-0.71	-0.7	0.44	-0.07	-0.65	-0.43	0.14		-0.4	-0.62	-0.78	-0.5
Net Interest Income	0.08	-0.07	0.31	0.02	-0.24	-0.3	-0.3	0.05	0.02	0.3	0.03	-0.13	-0.04	-0.03	0.02	-0.33	-0.08	0.06	0.35	-0.4		0.31	0.06	-0.19
Non Operating Income Net Other	0.7	0.31	0.71	0.78	0.04	-0.27	-0.02	0.79	-0.28	0.02	-0.19	-0.59	0.78	0.77	-0.29	0.28	0.7	0.53	-0.09	-0.62	0.31		0.76	0.67
Selling And Marketing Expenses	0.84	0.51	0.89	0.98	0.16	-0.41	-0.11	0.97	-0.55	-0.31	-0.54	-0.06	0.96	0.92	-0.56	0.46	0.95	0.46	-0.25	-0.78	0.06	0.76		0.71
Reconciled Depreciation	0.62	0.62	0.61	0.78	0.32	-0.33	-0.12	0.76	-0.6	-0.42	-0.54	-0.26	0.76	0.72	-0.62	0.62	0.8	0.52	-0.28	-0.5	-0.19	0.67	0.71

Click cells to compare fundamentals

Aytu BioScience Account Relationship Matchups

Aytu BioScience income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	236.6K	10.1M	8.8M	8.3M	9.5M	10.0M
Interest Expense	37.5M	147.5M	5.0M	4.8M	5.5M	5.2M
Selling General Administrative	25.5M	31.2M	28.6M	22.5M	25.9M	27.2M
Other Operating Expenses	103.9M	132.8M	124.5M	86.3M	99.2M	104.2M
Operating Income	(38.2M)	37.2M	(17.1M)	(5.3M)	(4.7M)	(5.0M)
Ebit	(14.7M)	(38.1M)	(12.1M)	(9.3M)	(8.4M)	(8.8M)
Ebitda	(14.5M)	(28.0M)	(3.3M)	(1.0M)	(910.8K)	(956.3K)
Total Operating Expenses	67.4M	88.4M	83.7M	60.6M	69.7M	73.1M
Income Before Tax	(58.0M)	(110.3M)	(17.1M)	(14.1M)	(12.7M)	(13.3M)
Total Other Income Expense Net	(19.8M)	1.0M	14K	(8.8M)	(7.9M)	(7.5M)
Net Income	(58.3M)	(108.8M)	(17.1M)	(15.8M)	(14.3M)	(15.0M)
Income Tax Expense	259K	(110K)	(57K)	1.8M	2.0M	1.2M
Total Revenue	65.6M	96.7M	107.4M	81.0M	93.2M	97.8M
Gross Profit	29.2M	52.3M	66.6M	54.6M	62.8M	65.9M
Net Income From Continuing Ops	(58.3M)	(110.2M)	(17.1M)	(15.8M)	(14.3M)	(15.0M)
Research Development	5.6M	14.4M	4.1M	2.8M	3.2M	4.3M
Cost Of Revenue	36.4M	44.4M	40.8M	26.4M	30.4M	15.4M
Net Income Applicable To Common Shares	(13.6M)	(58.3M)	(110.2M)	(17.1M)	(15.3M)	(16.1M)
Selling And Marketing Expenses	30.3M	38.7M	41.4M	27.0M	31.0M	27.3M
Reconciled Depreciation	9.2M	10.3M	4.8M	8.3M	9.5M	6.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Aytu Historical Income Statement

About Aytu Income Statement Analysis

Aytu BioScience Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Total Revenue

Aytu BioScience income statement Correlations

Aytu BioScience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aytu BioScience income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aytu Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Gross Profit	+ 0.99	Total Revenue
Selling And Marketing Expenses	+ 0.98	Other Operating Expenses
Net Income	+ 0.98	Income Before Tax
Net Income From Continuing Ops	+ 0.98	Net Income

Non Recurring	- 0.95	Selling General Administrative
Net Income From Continuing Ops	- 0.94	Interest Expense
Income Before Tax	- 0.94	Interest Expense
Net Income	- 0.89	Interest Expense
Research Development	- 0.84	Net Income From Continuing Ops
Research Development	- 0.84	Income Before Tax